ERBB2 and cancer: Mechanistically, in premalignant lesions, CCL2 produced by cancer cells and myeloid cells attracted CD206+/Tie2+ macrophages and induced Wnt-1 upregulation, which in turn downregulated E-cadherin junctions in HER2+ early cancer cells.